Merck (MSD) has signed a definitive agreement to acquire all outstanding shares of clinical-stage biopharmaceutical firm OncoImmune through a subsidiary, for an upfront payment of $425m in cash.
Under the deal, OncoImmune shareholders will receive sales-based payments and payments contingent on achieving certain regulatory milestones.
Go deeper with GlobalData
With this deal, Merck will add OncoImunne’s clinical programmes in response to Covid-19 to its suite.
The company will also accelerate the development of the Covid-19 therapeutic candidate, CD24Fc.
In September, OncoImmune reported positive top-line findings from an interim efficacy analysis of a Phase III SAC-COVID trial of CD24Fc for treating severe or critical Covid-19 patients.
Results showed that patients with severe or critical Covid-19 given a single dose of CD24Fc showed a 60% higher probability of improvement in clinical status versus placebo.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMerck Research Laboratories president Dr Roger Perlmutter said: “Meaningful new therapeutic options are desperately needed for possibly millions of people around the world who will develop severe or critical Covid-19 disease.
“Recent clinical investigations support the view that CD24Fc may provide benefit beyond standard of care therapy for Covid-19 patients requiring oxygen support, and hence will represent an important addition to the Merck pipeline of investigational medicines and vaccines designed to address the Covid-19 pandemic.”
Before the closing of the deal, expected before this year-end, OncoImmune will spin-out certain rights and assets unrelated to the CD24Fc programme to a new entity.
In addition, Merck will invest $50m and become a minority shareholder in the new entity owned by the OncoImmune’s existing shareholders.
In April, the US FDA gave approval to OncoImmune to conduct a Phase III trial of CD24Fc to treat patients with Covid-19.
